Aeterna Zentaris Inc.
https://www.zentaris.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Aeterna Zentaris Inc.
BridgeBio Spins Out Cancer Arm With $200m Fundraise
BridgeBio will narrow its focus to rare diseases and the November action date for acoramidis, while subsidiary TheRas will become BridgeBio Oncology Therapeutics, focused on KRAS-targeted drugs.
What’s The Key To Successful R&D With Artificial Intelligence? ‘Bilingual’ Scientists
Before J&J’s former chief data scientist Najat Khan moved to Recursion, she talked to the Pink Sheet about how AI is transforming trials and driving collaboration between industry and regulators.
The UK’s Cancer Vaccine Partnership With BioNTech Is Another First – But Can It Deliver?
BioNTech and the UK government's alliance to bring personalized cancer immunotherapy to patients is making progress, but the National Health Service has to show it can deliver on clinical trials recruitment.
NASDAQ Is Nice But Home Provides Comfort For Europe’s Biotechs
The attraction of listing in the US for innovative companies is clear but the heads of the Swiss Biotech Association tell Scrip that start-ups should remember the advantages of playing at home and not waste too much energy and time on worrying about being on the NASDAQ.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Specialty Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice